nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—CYP1A1—Dacarbazine—sarcoma	0.0921	0.196	CbGbCtD
Thalidomide—CYP2E1—Dacarbazine—sarcoma	0.0711	0.152	CbGbCtD
Thalidomide—CYP2E1—Mitoxantrone—sarcoma	0.0552	0.118	CbGbCtD
Thalidomide—PTGS2—Etoposide—sarcoma	0.0534	0.114	CbGbCtD
Thalidomide—PTGS1—Etoposide—sarcoma	0.0451	0.096	CbGbCtD
Thalidomide—CYP1A2—Dacarbazine—sarcoma	0.0411	0.0876	CbGbCtD
Thalidomide—CYP2E1—Etoposide—sarcoma	0.0348	0.0741	CbGbCtD
Thalidomide—CYP3A5—Vincristine—sarcoma	0.0295	0.0629	CbGbCtD
Thalidomide—CYP3A5—Etoposide—sarcoma	0.027	0.0576	CbGbCtD
Thalidomide—CYP1A2—Etoposide—sarcoma	0.0201	0.0429	CbGbCtD
Thalidomide—FGFR2—skull—sarcoma	0.00724	0.0784	CbGeAlD
Thalidomide—NFKB1—mammary gland—sarcoma	0.00349	0.0377	CbGeAlD
Thalidomide—PTGS2—periosteum—sarcoma	0.00268	0.029	CbGeAlD
Thalidomide—FGFR2—mammary gland—sarcoma	0.00262	0.0283	CbGeAlD
Thalidomide—NFKB1—myometrium—sarcoma	0.00247	0.0268	CbGeAlD
Thalidomide—NFKB1—seminal vesicle—sarcoma	0.00223	0.0242	CbGeAlD
Thalidomide—PTGS2—leg—sarcoma	0.00213	0.0231	CbGeAlD
Thalidomide—NFKB1—hematopoietic system—sarcoma	0.00212	0.023	CbGeAlD
Thalidomide—CRBN—myometrium—sarcoma	0.00207	0.0224	CbGeAlD
Thalidomide—NFKB1—connective tissue—sarcoma	0.00205	0.0221	CbGeAlD
Thalidomide—CRBN—embryo—sarcoma	0.00199	0.0216	CbGeAlD
Thalidomide—PTGS2—hindlimb—sarcoma	0.00191	0.0206	CbGeAlD
Thalidomide—PTGS2—cartilage tissue—sarcoma	0.00188	0.0203	CbGeAlD
Thalidomide—CRBN—seminal vesicle—sarcoma	0.00187	0.0203	CbGeAlD
Thalidomide—FGFR2—embryo—sarcoma	0.00179	0.0193	CbGeAlD
Thalidomide—CRBN—hematopoietic system—sarcoma	0.00178	0.0193	CbGeAlD
Thalidomide—PTGS2—appendage—sarcoma	0.00164	0.0177	CbGeAlD
Thalidomide—NFKB1—cardiac atrium—sarcoma	0.00161	0.0175	CbGeAlD
Thalidomide—NFKB1—uterus—sarcoma	0.0016	0.0174	CbGeAlD
Thalidomide—FGFR2—hematopoietic system—sarcoma	0.0016	0.0173	CbGeAlD
Thalidomide—FGFR2—connective tissue—sarcoma	0.00154	0.0166	CbGeAlD
Thalidomide—NFKB1—lymphoid tissue—sarcoma	0.0015	0.0162	CbGeAlD
Thalidomide—TNF—lymph node—sarcoma	0.00148	0.016	CbGeAlD
Thalidomide—NFKB1—tendon—sarcoma	0.00141	0.0152	CbGeAlD
Thalidomide—FGFR2—smooth muscle tissue—sarcoma	0.00141	0.0152	CbGeAlD
Thalidomide—FGFR2—skin of body—sarcoma	0.00139	0.015	CbGeAlD
Thalidomide—NFKB1—bone marrow—sarcoma	0.00136	0.0147	CbGeAlD
Thalidomide—CRBN—cardiac atrium—sarcoma	0.00135	0.0146	CbGeAlD
Thalidomide—CRBN—uterus—sarcoma	0.00134	0.0146	CbGeAlD
Thalidomide—CRBN—lymphoid tissue—sarcoma	0.00125	0.0136	CbGeAlD
Thalidomide—FGFR2—uterus—sarcoma	0.00121	0.013	CbGeAlD
Thalidomide—CRBN—tendon—sarcoma	0.00118	0.0128	CbGeAlD
Thalidomide—NFKB1—testis—sarcoma	0.00116	0.0126	CbGeAlD
Thalidomide—CRBN—bone marrow—sarcoma	0.00114	0.0124	CbGeAlD
Thalidomide—NFKB1—liver—sarcoma	0.0011	0.0119	CbGeAlD
Thalidomide—PTGS1—endothelium—sarcoma	0.00103	0.0112	CbGeAlD
Thalidomide—PTGS2—endothelium—sarcoma	0.000987	0.0107	CbGeAlD
Thalidomide—CRBN—testis—sarcoma	0.000976	0.0106	CbGeAlD
Thalidomide—CRBN—liver—sarcoma	0.000922	0.00998	CbGeAlD
Thalidomide—CYP2C9—mammary gland—sarcoma	0.000912	0.00987	CbGeAlD
Thalidomide—FGFR2—testis—sarcoma	0.000874	0.00946	CbGeAlD
Thalidomide—NFKB1—lymph node—sarcoma	0.000844	0.00913	CbGeAlD
Thalidomide—FGFR2—liver—sarcoma	0.000827	0.00895	CbGeAlD
Thalidomide—CYP2C19—hematopoietic system—sarcoma	0.000717	0.00776	CbGeAlD
Thalidomide—CRBN—lymph node—sarcoma	0.000707	0.00765	CbGeAlD
Thalidomide—CYP1A2—hematopoietic system—sarcoma	0.000585	0.00633	CbGeAlD
Thalidomide—CYP1A1—hematopoietic system—sarcoma	0.000577	0.00625	CbGeAlD
Thalidomide—PTGS2—myometrium—sarcoma	0.000565	0.00611	CbGeAlD
Thalidomide—CYP3A5—hematopoietic system—sarcoma	0.000565	0.00611	CbGeAlD
Thalidomide—CYP2C9—hematopoietic system—sarcoma	0.000556	0.00601	CbGeAlD
Thalidomide—CYP2E1—seminal vesicle—sarcoma	0.000554	0.006	CbGeAlD
Thalidomide—PTGS2—embryo—sarcoma	0.000543	0.00588	CbGeAlD
Thalidomide—PTGS1—seminal vesicle—sarcoma	0.000534	0.00578	CbGeAlD
Thalidomide—CYP2E1—hematopoietic system—sarcoma	0.000527	0.0057	CbGeAlD
Thalidomide—PTGS2—seminal vesicle—sarcoma	0.00051	0.00552	CbGeAlD
Thalidomide—PTGS1—hematopoietic system—sarcoma	0.000507	0.00549	CbGeAlD
Thalidomide—CYP1A1—skin of body—sarcoma	0.000502	0.00543	CbGeAlD
Thalidomide—PTGS1—connective tissue—sarcoma	0.000488	0.00529	CbGeAlD
Thalidomide—PTGS2—hematopoietic system—sarcoma	0.000485	0.00525	CbGeAlD
Thalidomide—PTGS2—connective tissue—sarcoma	0.000467	0.00505	CbGeAlD
Thalidomide—PTGS1—smooth muscle tissue—sarcoma	0.000447	0.00484	CbGeAlD
Thalidomide—PTGS1—skin of body—sarcoma	0.000441	0.00477	CbGeAlD
Thalidomide—CYP1A1—cardiac atrium—sarcoma	0.000438	0.00474	CbGeAlD
Thalidomide—CYP1A1—uterus—sarcoma	0.000436	0.00472	CbGeAlD
Thalidomide—PTGS2—smooth muscle tissue—sarcoma	0.000427	0.00462	CbGeAlD
Thalidomide—PTGS2—skin of body—sarcoma	0.000422	0.00456	CbGeAlD
Thalidomide—PTGS1—cardiac atrium—sarcoma	0.000385	0.00417	CbGeAlD
Thalidomide—PTGS1—uterus—sarcoma	0.000383	0.00415	CbGeAlD
Thalidomide—CYP2C19—liver—sarcoma	0.000371	0.00402	CbGeAlD
Thalidomide—CYP2E1—lymphoid tissue—sarcoma	0.000371	0.00401	CbGeAlD
Thalidomide—PTGS2—uterus—sarcoma	0.000366	0.00396	CbGeAlD
Thalidomide—CYP2E1—tendon—sarcoma	0.000348	0.00377	CbGeAlD
Thalidomide—PTGS2—lymphoid tissue—sarcoma	0.000341	0.00369	CbGeAlD
Thalidomide—PTGS1—tendon—sarcoma	0.000336	0.00363	CbGeAlD
Thalidomide—PTGS2—tendon—sarcoma	0.000321	0.00347	CbGeAlD
Thalidomide—PTGS2—bone marrow—sarcoma	0.000311	0.00336	CbGeAlD
Thalidomide—CYP1A2—liver—sarcoma	0.000303	0.00328	CbGeAlD
Thalidomide—CYP1A1—liver—sarcoma	0.000299	0.00324	CbGeAlD
Thalidomide—CYP3A5—liver—sarcoma	0.000292	0.00317	CbGeAlD
Thalidomide—CYP2E1—testis—sarcoma	0.000289	0.00312	CbGeAlD
Thalidomide—CYP2C9—liver—sarcoma	0.000288	0.00312	CbGeAlD
Thalidomide—PTGS1—testis—sarcoma	0.000278	0.00301	CbGeAlD
Thalidomide—CYP2E1—liver—sarcoma	0.000273	0.00295	CbGeAlD
Thalidomide—PTGS2—liver—sarcoma	0.000251	0.00272	CbGeAlD
Thalidomide—CYP1A1—lymph node—sarcoma	0.000229	0.00248	CbGeAlD
Thalidomide—PTGS1—lymph node—sarcoma	0.000201	0.00218	CbGeAlD
Thalidomide—PTGS2—lymph node—sarcoma	0.000193	0.00208	CbGeAlD
Thalidomide—Angina pectoris—Doxorubicin—sarcoma	0.000119	0.000448	CcSEcCtD
Thalidomide—Hypersensitivity—Mitoxantrone—sarcoma	0.000119	0.000447	CcSEcCtD
Thalidomide—Asthenia—Vincristine—sarcoma	0.000119	0.000447	CcSEcCtD
Thalidomide—Vomiting—Thiotepa—sarcoma	0.000119	0.000446	CcSEcCtD
Thalidomide—Pneumonia—Epirubicin—sarcoma	0.000119	0.000446	CcSEcCtD
Thalidomide—Drowsiness—Epirubicin—sarcoma	0.000118	0.000443	CcSEcCtD
Thalidomide—Infestation NOS—Epirubicin—sarcoma	0.000118	0.000443	CcSEcCtD
Thalidomide—Infestation—Epirubicin—sarcoma	0.000118	0.000443	CcSEcCtD
Thalidomide—Vomiting—Dactinomycin—sarcoma	0.000118	0.000443	CcSEcCtD
Thalidomide—Rash—Thiotepa—sarcoma	0.000118	0.000443	CcSEcCtD
Thalidomide—Bronchitis—Doxorubicin—sarcoma	0.000118	0.000442	CcSEcCtD
Thalidomide—Dermatitis—Thiotepa—sarcoma	0.000118	0.000442	CcSEcCtD
Thalidomide—Headache—Thiotepa—sarcoma	0.000117	0.00044	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.000117	0.000439	CcSEcCtD
Thalidomide—Rash—Dactinomycin—sarcoma	0.000117	0.000439	CcSEcCtD
Thalidomide—Decreased appetite—Etoposide—sarcoma	0.000117	0.000438	CcSEcCtD
Thalidomide—Pancytopenia—Doxorubicin—sarcoma	0.000116	0.000437	CcSEcCtD
Thalidomide—Renal failure—Epirubicin—sarcoma	0.000116	0.000436	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Etoposide—sarcoma	0.000116	0.000435	CcSEcCtD
Thalidomide—Asthenia—Mitoxantrone—sarcoma	0.000116	0.000435	CcSEcCtD
Thalidomide—Fatigue—Etoposide—sarcoma	0.000116	0.000435	CcSEcCtD
Thalidomide—Neuropathy peripheral—Epirubicin—sarcoma	0.000116	0.000435	CcSEcCtD
Thalidomide—Stomatitis—Epirubicin—sarcoma	0.000115	0.000432	CcSEcCtD
Thalidomide—Pain—Etoposide—sarcoma	0.000115	0.000431	CcSEcCtD
Thalidomide—Constipation—Etoposide—sarcoma	0.000115	0.000431	CcSEcCtD
Thalidomide—Conjunctivitis—Epirubicin—sarcoma	0.000115	0.000431	CcSEcCtD
Thalidomide—Neutropenia—Doxorubicin—sarcoma	0.000114	0.00043	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000114	0.000428	CcSEcCtD
Thalidomide—Diarrhoea—Vincristine—sarcoma	0.000113	0.000426	CcSEcCtD
Thalidomide—Sweating—Epirubicin—sarcoma	0.000113	0.000425	CcSEcCtD
Thalidomide—Pollakiuria—Doxorubicin—sarcoma	0.000113	0.000425	CcSEcCtD
Thalidomide—Haematuria—Epirubicin—sarcoma	0.000112	0.000423	CcSEcCtD
Thalidomide—Photosensitivity reaction—Doxorubicin—sarcoma	0.000112	0.00042	CcSEcCtD
Thalidomide—Weight increased—Doxorubicin—sarcoma	0.000111	0.000419	CcSEcCtD
Thalidomide—Epistaxis—Epirubicin—sarcoma	0.000111	0.000418	CcSEcCtD
Thalidomide—Nausea—Thiotepa—sarcoma	0.000111	0.000417	CcSEcCtD
Thalidomide—Weight decreased—Doxorubicin—sarcoma	0.000111	0.000416	CcSEcCtD
Thalidomide—Sinusitis—Epirubicin—sarcoma	0.000111	0.000416	CcSEcCtD
Thalidomide—Feeling abnormal—Etoposide—sarcoma	0.000111	0.000416	CcSEcCtD
Thalidomide—Hyperglycaemia—Doxorubicin—sarcoma	0.00011	0.000415	CcSEcCtD
Thalidomide—Diarrhoea—Mitoxantrone—sarcoma	0.00011	0.000415	CcSEcCtD
Thalidomide—Nausea—Dactinomycin—sarcoma	0.00011	0.000414	CcSEcCtD
Thalidomide—Agranulocytosis—Epirubicin—sarcoma	0.00011	0.000414	CcSEcCtD
Thalidomide—Pneumonia—Doxorubicin—sarcoma	0.00011	0.000413	CcSEcCtD
Thalidomide—Gastrointestinal pain—Etoposide—sarcoma	0.00011	0.000412	CcSEcCtD
Thalidomide—Dizziness—Vincristine—sarcoma	0.00011	0.000412	CcSEcCtD
Thalidomide—Drowsiness—Doxorubicin—sarcoma	0.000109	0.00041	CcSEcCtD
Thalidomide—Infestation—Doxorubicin—sarcoma	0.000109	0.00041	CcSEcCtD
Thalidomide—Infestation NOS—Doxorubicin—sarcoma	0.000109	0.00041	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.000108	0.000407	CcSEcCtD
Thalidomide—Bradycardia—Epirubicin—sarcoma	0.000108	0.000405	CcSEcCtD
Thalidomide—Renal failure—Doxorubicin—sarcoma	0.000107	0.000403	CcSEcCtD
Thalidomide—Neuropathy peripheral—Doxorubicin—sarcoma	0.000107	0.000402	CcSEcCtD
Thalidomide—Urticaria—Etoposide—sarcoma	0.000107	0.000401	CcSEcCtD
Thalidomide—Stomatitis—Doxorubicin—sarcoma	0.000106	0.0004	CcSEcCtD
Thalidomide—Rhinitis—Epirubicin—sarcoma	0.000106	0.000399	CcSEcCtD
Thalidomide—Body temperature increased—Etoposide—sarcoma	0.000106	0.000399	CcSEcCtD
Thalidomide—Abdominal pain—Etoposide—sarcoma	0.000106	0.000399	CcSEcCtD
Thalidomide—Conjunctivitis—Doxorubicin—sarcoma	0.000106	0.000399	CcSEcCtD
Thalidomide—Hepatitis—Epirubicin—sarcoma	0.000106	0.000398	CcSEcCtD
Thalidomide—Hypoaesthesia—Epirubicin—sarcoma	0.000105	0.000396	CcSEcCtD
Thalidomide—Vomiting—Vincristine—sarcoma	0.000105	0.000396	CcSEcCtD
Thalidomide—Pharyngitis—Epirubicin—sarcoma	0.000105	0.000395	CcSEcCtD
Thalidomide—Sweating—Doxorubicin—sarcoma	0.000105	0.000393	CcSEcCtD
Thalidomide—Urinary tract disorder—Epirubicin—sarcoma	0.000105	0.000393	CcSEcCtD
Thalidomide—Rash—Vincristine—sarcoma	0.000104	0.000393	CcSEcCtD
Thalidomide—Dermatitis—Vincristine—sarcoma	0.000104	0.000392	CcSEcCtD
Thalidomide—Oedema peripheral—Epirubicin—sarcoma	0.000104	0.000392	CcSEcCtD
Thalidomide—Haematuria—Doxorubicin—sarcoma	0.000104	0.000391	CcSEcCtD
Thalidomide—Urethral disorder—Epirubicin—sarcoma	0.000104	0.00039	CcSEcCtD
Thalidomide—Headache—Vincristine—sarcoma	0.000104	0.00039	CcSEcCtD
Thalidomide—Epistaxis—Doxorubicin—sarcoma	0.000103	0.000387	CcSEcCtD
Thalidomide—Vomiting—Mitoxantrone—sarcoma	0.000103	0.000386	CcSEcCtD
Thalidomide—Sinusitis—Doxorubicin—sarcoma	0.000102	0.000385	CcSEcCtD
Thalidomide—Visual impairment—Epirubicin—sarcoma	0.000102	0.000383	CcSEcCtD
Thalidomide—Agranulocytosis—Doxorubicin—sarcoma	0.000102	0.000383	CcSEcCtD
Thalidomide—Rash—Mitoxantrone—sarcoma	0.000102	0.000382	CcSEcCtD
Thalidomide—Dermatitis—Mitoxantrone—sarcoma	0.000102	0.000382	CcSEcCtD
Thalidomide—Headache—Mitoxantrone—sarcoma	0.000101	0.00038	CcSEcCtD
Thalidomide—Erythema multiforme—Epirubicin—sarcoma	0.0001	0.000376	CcSEcCtD
Thalidomide—Bradycardia—Doxorubicin—sarcoma	9.97e-05	0.000375	CcSEcCtD
Thalidomide—Eye disorder—Epirubicin—sarcoma	9.89e-05	0.000372	CcSEcCtD
Thalidomide—Hypersensitivity—Etoposide—sarcoma	9.88e-05	0.000372	CcSEcCtD
Thalidomide—Tinnitus—Epirubicin—sarcoma	9.87e-05	0.000371	CcSEcCtD
Thalidomide—Nausea—Vincristine—sarcoma	9.84e-05	0.00037	CcSEcCtD
Thalidomide—Cardiac disorder—Epirubicin—sarcoma	9.82e-05	0.000369	CcSEcCtD
Thalidomide—Rhinitis—Doxorubicin—sarcoma	9.82e-05	0.000369	CcSEcCtD
Thalidomide—Hepatitis—Doxorubicin—sarcoma	9.79e-05	0.000368	CcSEcCtD
Thalidomide—Hypoaesthesia—Doxorubicin—sarcoma	9.74e-05	0.000366	CcSEcCtD
Thalidomide—Pharyngitis—Doxorubicin—sarcoma	9.72e-05	0.000365	CcSEcCtD
Thalidomide—Urinary tract disorder—Doxorubicin—sarcoma	9.67e-05	0.000364	CcSEcCtD
Thalidomide—Oedema peripheral—Doxorubicin—sarcoma	9.65e-05	0.000363	CcSEcCtD
Thalidomide—Asthenia—Etoposide—sarcoma	9.63e-05	0.000362	CcSEcCtD
Thalidomide—Angiopathy—Epirubicin—sarcoma	9.6e-05	0.000361	CcSEcCtD
Thalidomide—Urethral disorder—Doxorubicin—sarcoma	9.6e-05	0.000361	CcSEcCtD
Thalidomide—Nausea—Mitoxantrone—sarcoma	9.58e-05	0.00036	CcSEcCtD
Thalidomide—Immune system disorder—Epirubicin—sarcoma	9.56e-05	0.000359	CcSEcCtD
Thalidomide—Mediastinal disorder—Epirubicin—sarcoma	9.54e-05	0.000359	CcSEcCtD
Thalidomide—Chills—Epirubicin—sarcoma	9.5e-05	0.000357	CcSEcCtD
Thalidomide—Pruritus—Etoposide—sarcoma	9.49e-05	0.000357	CcSEcCtD
Thalidomide—Arrhythmia—Epirubicin—sarcoma	9.46e-05	0.000355	CcSEcCtD
Thalidomide—Visual impairment—Doxorubicin—sarcoma	9.44e-05	0.000355	CcSEcCtD
Thalidomide—Alopecia—Epirubicin—sarcoma	9.35e-05	0.000352	CcSEcCtD
Thalidomide—Mental disorder—Epirubicin—sarcoma	9.27e-05	0.000349	CcSEcCtD
Thalidomide—Erythema multiforme—Doxorubicin—sarcoma	9.26e-05	0.000348	CcSEcCtD
Thalidomide—Malnutrition—Epirubicin—sarcoma	9.21e-05	0.000346	CcSEcCtD
Thalidomide—Diarrhoea—Etoposide—sarcoma	9.18e-05	0.000345	CcSEcCtD
Thalidomide—Eye disorder—Doxorubicin—sarcoma	9.15e-05	0.000344	CcSEcCtD
Thalidomide—Tinnitus—Doxorubicin—sarcoma	9.13e-05	0.000343	CcSEcCtD
Thalidomide—Cardiac disorder—Doxorubicin—sarcoma	9.09e-05	0.000342	CcSEcCtD
Thalidomide—Flatulence—Epirubicin—sarcoma	9.08e-05	0.000341	CcSEcCtD
Thalidomide—Tension—Epirubicin—sarcoma	9.04e-05	0.00034	CcSEcCtD
Thalidomide—Dysgeusia—Epirubicin—sarcoma	9.02e-05	0.000339	CcSEcCtD
Thalidomide—Nervousness—Epirubicin—sarcoma	8.95e-05	0.000336	CcSEcCtD
Thalidomide—Back pain—Epirubicin—sarcoma	8.91e-05	0.000335	CcSEcCtD
Thalidomide—Angiopathy—Doxorubicin—sarcoma	8.89e-05	0.000334	CcSEcCtD
Thalidomide—Dizziness—Etoposide—sarcoma	8.87e-05	0.000334	CcSEcCtD
Thalidomide—Muscle spasms—Epirubicin—sarcoma	8.86e-05	0.000333	CcSEcCtD
Thalidomide—Immune system disorder—Doxorubicin—sarcoma	8.85e-05	0.000333	CcSEcCtD
Thalidomide—Mediastinal disorder—Doxorubicin—sarcoma	8.83e-05	0.000332	CcSEcCtD
Thalidomide—Chills—Doxorubicin—sarcoma	8.79e-05	0.00033	CcSEcCtD
Thalidomide—Arrhythmia—Doxorubicin—sarcoma	8.75e-05	0.000329	CcSEcCtD
Thalidomide—Vision blurred—Epirubicin—sarcoma	8.68e-05	0.000326	CcSEcCtD
Thalidomide—Alopecia—Doxorubicin—sarcoma	8.65e-05	0.000325	CcSEcCtD
Thalidomide—Mental disorder—Doxorubicin—sarcoma	8.58e-05	0.000323	CcSEcCtD
Thalidomide—Ill-defined disorder—Epirubicin—sarcoma	8.55e-05	0.000321	CcSEcCtD
Thalidomide—Vomiting—Etoposide—sarcoma	8.53e-05	0.000321	CcSEcCtD
Thalidomide—Malnutrition—Doxorubicin—sarcoma	8.53e-05	0.000321	CcSEcCtD
Thalidomide—Anaemia—Epirubicin—sarcoma	8.52e-05	0.00032	CcSEcCtD
Thalidomide—Agitation—Epirubicin—sarcoma	8.47e-05	0.000318	CcSEcCtD
Thalidomide—Rash—Etoposide—sarcoma	8.46e-05	0.000318	CcSEcCtD
Thalidomide—Dermatitis—Etoposide—sarcoma	8.45e-05	0.000318	CcSEcCtD
Thalidomide—Headache—Etoposide—sarcoma	8.4e-05	0.000316	CcSEcCtD
Thalidomide—Flatulence—Doxorubicin—sarcoma	8.4e-05	0.000316	CcSEcCtD
Thalidomide—Tension—Doxorubicin—sarcoma	8.37e-05	0.000315	CcSEcCtD
Thalidomide—Dysgeusia—Doxorubicin—sarcoma	8.35e-05	0.000314	CcSEcCtD
Thalidomide—Malaise—Epirubicin—sarcoma	8.31e-05	0.000312	CcSEcCtD
Thalidomide—Nervousness—Doxorubicin—sarcoma	8.28e-05	0.000311	CcSEcCtD
Thalidomide—Vertigo—Epirubicin—sarcoma	8.28e-05	0.000311	CcSEcCtD
Thalidomide—Syncope—Epirubicin—sarcoma	8.26e-05	0.000311	CcSEcCtD
Thalidomide—Leukopenia—Epirubicin—sarcoma	8.25e-05	0.00031	CcSEcCtD
Thalidomide—Back pain—Doxorubicin—sarcoma	8.25e-05	0.00031	CcSEcCtD
Thalidomide—Muscle spasms—Doxorubicin—sarcoma	8.2e-05	0.000308	CcSEcCtD
Thalidomide—Palpitations—Epirubicin—sarcoma	8.14e-05	0.000306	CcSEcCtD
Thalidomide—Loss of consciousness—Epirubicin—sarcoma	8.1e-05	0.000304	CcSEcCtD
Thalidomide—Cough—Epirubicin—sarcoma	8.04e-05	0.000302	CcSEcCtD
Thalidomide—Vision blurred—Doxorubicin—sarcoma	8.04e-05	0.000302	CcSEcCtD
Thalidomide—Convulsion—Epirubicin—sarcoma	7.98e-05	0.0003	CcSEcCtD
Thalidomide—Nausea—Etoposide—sarcoma	7.97e-05	0.0003	CcSEcCtD
Thalidomide—Hypertension—Epirubicin—sarcoma	7.96e-05	0.000299	CcSEcCtD
Thalidomide—Ill-defined disorder—Doxorubicin—sarcoma	7.91e-05	0.000297	CcSEcCtD
Thalidomide—Anaemia—Doxorubicin—sarcoma	7.88e-05	0.000296	CcSEcCtD
Thalidomide—Chest pain—Epirubicin—sarcoma	7.84e-05	0.000295	CcSEcCtD
Thalidomide—Myalgia—Epirubicin—sarcoma	7.84e-05	0.000295	CcSEcCtD
Thalidomide—Arthralgia—Epirubicin—sarcoma	7.84e-05	0.000295	CcSEcCtD
Thalidomide—Agitation—Doxorubicin—sarcoma	7.83e-05	0.000295	CcSEcCtD
Thalidomide—Anxiety—Epirubicin—sarcoma	7.82e-05	0.000294	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	7.79e-05	0.000293	CcSEcCtD
Thalidomide—Discomfort—Epirubicin—sarcoma	7.75e-05	0.000291	CcSEcCtD
Thalidomide—Malaise—Doxorubicin—sarcoma	7.69e-05	0.000289	CcSEcCtD
Thalidomide—Dry mouth—Epirubicin—sarcoma	7.67e-05	0.000288	CcSEcCtD
Thalidomide—Vertigo—Doxorubicin—sarcoma	7.66e-05	0.000288	CcSEcCtD
Thalidomide—Syncope—Doxorubicin—sarcoma	7.65e-05	0.000287	CcSEcCtD
Thalidomide—Leukopenia—Doxorubicin—sarcoma	7.63e-05	0.000287	CcSEcCtD
Thalidomide—Confusional state—Epirubicin—sarcoma	7.58e-05	0.000285	CcSEcCtD
Thalidomide—Palpitations—Doxorubicin—sarcoma	7.53e-05	0.000283	CcSEcCtD
Thalidomide—Oedema—Epirubicin—sarcoma	7.52e-05	0.000283	CcSEcCtD
Thalidomide—Loss of consciousness—Doxorubicin—sarcoma	7.49e-05	0.000282	CcSEcCtD
Thalidomide—Infection—Epirubicin—sarcoma	7.47e-05	0.000281	CcSEcCtD
Thalidomide—Cough—Doxorubicin—sarcoma	7.44e-05	0.00028	CcSEcCtD
Thalidomide—Shock—Epirubicin—sarcoma	7.4e-05	0.000278	CcSEcCtD
Thalidomide—Convulsion—Doxorubicin—sarcoma	7.39e-05	0.000278	CcSEcCtD
Thalidomide—Nervous system disorder—Epirubicin—sarcoma	7.37e-05	0.000277	CcSEcCtD
Thalidomide—Thrombocytopenia—Epirubicin—sarcoma	7.36e-05	0.000277	CcSEcCtD
Thalidomide—Hypertension—Doxorubicin—sarcoma	7.36e-05	0.000277	CcSEcCtD
Thalidomide—Tachycardia—Epirubicin—sarcoma	7.34e-05	0.000276	CcSEcCtD
Thalidomide—Skin disorder—Epirubicin—sarcoma	7.3e-05	0.000275	CcSEcCtD
Thalidomide—Hyperhidrosis—Epirubicin—sarcoma	7.27e-05	0.000273	CcSEcCtD
Thalidomide—Myalgia—Doxorubicin—sarcoma	7.26e-05	0.000273	CcSEcCtD
Thalidomide—Chest pain—Doxorubicin—sarcoma	7.26e-05	0.000273	CcSEcCtD
Thalidomide—Arthralgia—Doxorubicin—sarcoma	7.26e-05	0.000273	CcSEcCtD
Thalidomide—Anxiety—Doxorubicin—sarcoma	7.23e-05	0.000272	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	7.21e-05	0.000271	CcSEcCtD
Thalidomide—Discomfort—Doxorubicin—sarcoma	7.17e-05	0.00027	CcSEcCtD
Thalidomide—Anorexia—Epirubicin—sarcoma	7.17e-05	0.000269	CcSEcCtD
Thalidomide—Dry mouth—Doxorubicin—sarcoma	7.1e-05	0.000267	CcSEcCtD
Thalidomide—Hypotension—Epirubicin—sarcoma	7.03e-05	0.000264	CcSEcCtD
Thalidomide—Confusional state—Doxorubicin—sarcoma	7.02e-05	0.000264	CcSEcCtD
Thalidomide—Oedema—Doxorubicin—sarcoma	6.96e-05	0.000262	CcSEcCtD
Thalidomide—Infection—Doxorubicin—sarcoma	6.91e-05	0.00026	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Epirubicin—sarcoma	6.85e-05	0.000258	CcSEcCtD
Thalidomide—Shock—Doxorubicin—sarcoma	6.85e-05	0.000257	CcSEcCtD
Thalidomide—Nervous system disorder—Doxorubicin—sarcoma	6.82e-05	0.000257	CcSEcCtD
Thalidomide—Thrombocytopenia—Doxorubicin—sarcoma	6.81e-05	0.000256	CcSEcCtD
Thalidomide—Insomnia—Epirubicin—sarcoma	6.8e-05	0.000256	CcSEcCtD
Thalidomide—Tachycardia—Doxorubicin—sarcoma	6.79e-05	0.000255	CcSEcCtD
Thalidomide—Skin disorder—Doxorubicin—sarcoma	6.76e-05	0.000254	CcSEcCtD
Thalidomide—Paraesthesia—Epirubicin—sarcoma	6.75e-05	0.000254	CcSEcCtD
Thalidomide—Hyperhidrosis—Doxorubicin—sarcoma	6.73e-05	0.000253	CcSEcCtD
Thalidomide—Dyspnoea—Epirubicin—sarcoma	6.7e-05	0.000252	CcSEcCtD
Thalidomide—Somnolence—Epirubicin—sarcoma	6.69e-05	0.000251	CcSEcCtD
Thalidomide—Anorexia—Doxorubicin—sarcoma	6.63e-05	0.000249	CcSEcCtD
Thalidomide—Dyspepsia—Epirubicin—sarcoma	6.62e-05	0.000249	CcSEcCtD
Thalidomide—Decreased appetite—Epirubicin—sarcoma	6.54e-05	0.000246	CcSEcCtD
Thalidomide—Hypotension—Doxorubicin—sarcoma	6.5e-05	0.000244	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Epirubicin—sarcoma	6.49e-05	0.000244	CcSEcCtD
Thalidomide—Fatigue—Epirubicin—sarcoma	6.48e-05	0.000244	CcSEcCtD
Thalidomide—Constipation—Epirubicin—sarcoma	6.43e-05	0.000242	CcSEcCtD
Thalidomide—Pain—Epirubicin—sarcoma	6.43e-05	0.000242	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Doxorubicin—sarcoma	6.34e-05	0.000238	CcSEcCtD
Thalidomide—Insomnia—Doxorubicin—sarcoma	6.29e-05	0.000237	CcSEcCtD
Thalidomide—Paraesthesia—Doxorubicin—sarcoma	6.25e-05	0.000235	CcSEcCtD
Thalidomide—Dyspnoea—Doxorubicin—sarcoma	6.2e-05	0.000233	CcSEcCtD
Thalidomide—Feeling abnormal—Epirubicin—sarcoma	6.2e-05	0.000233	CcSEcCtD
Thalidomide—Somnolence—Doxorubicin—sarcoma	6.19e-05	0.000233	CcSEcCtD
Thalidomide—Gastrointestinal pain—Epirubicin—sarcoma	6.15e-05	0.000231	CcSEcCtD
Thalidomide—Dyspepsia—Doxorubicin—sarcoma	6.13e-05	0.00023	CcSEcCtD
Thalidomide—Decreased appetite—Doxorubicin—sarcoma	6.05e-05	0.000227	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Doxorubicin—sarcoma	6.01e-05	0.000226	CcSEcCtD
Thalidomide—Fatigue—Doxorubicin—sarcoma	6e-05	0.000226	CcSEcCtD
Thalidomide—NFKB1—Immune System—PTPRC—sarcoma	5.98e-05	0.000347	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—EGFR—sarcoma	5.98e-05	0.000347	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—KRAS—sarcoma	5.97e-05	0.000347	CbGpPWpGaD
Thalidomide—Urticaria—Epirubicin—sarcoma	5.97e-05	0.000225	CcSEcCtD
Thalidomide—Constipation—Doxorubicin—sarcoma	5.95e-05	0.000224	CcSEcCtD
Thalidomide—Pain—Doxorubicin—sarcoma	5.95e-05	0.000224	CcSEcCtD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	5.95e-05	0.000345	CbGpPWpGaD
Thalidomide—Abdominal pain—Epirubicin—sarcoma	5.94e-05	0.000223	CcSEcCtD
Thalidomide—Body temperature increased—Epirubicin—sarcoma	5.94e-05	0.000223	CcSEcCtD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	5.9e-05	0.000343	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—sarcoma	5.9e-05	0.000342	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	5.9e-05	0.000342	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—CREB1—sarcoma	5.86e-05	0.00034	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PLCG1—sarcoma	5.85e-05	0.00034	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—SRC—sarcoma	5.85e-05	0.00034	CbGpPWpGaD
Thalidomide—Feeling abnormal—Doxorubicin—sarcoma	5.73e-05	0.000216	CcSEcCtD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—HRAS—sarcoma	5.73e-05	0.000333	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—HRAS—sarcoma	5.73e-05	0.000333	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—HRAS—sarcoma	5.73e-05	0.000333	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—NRAS—sarcoma	5.72e-05	0.000332	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TLE1—sarcoma	5.71e-05	0.000331	CbGpPWpGaD
Thalidomide—Gastrointestinal pain—Doxorubicin—sarcoma	5.69e-05	0.000214	CcSEcCtD
Thalidomide—FGFR2—Signaling by EGFR—HRAS—sarcoma	5.68e-05	0.00033	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PTPRC—sarcoma	5.67e-05	0.00033	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—KRAS—sarcoma	5.65e-05	0.000328	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—HRAS—sarcoma	5.63e-05	0.000327	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—NRAS—sarcoma	5.63e-05	0.000327	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—HRAS—sarcoma	5.61e-05	0.000326	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—HRAS—sarcoma	5.59e-05	0.000325	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	5.57e-05	0.000324	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ATF1—sarcoma	5.56e-05	0.000323	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PLCG1—sarcoma	5.55e-05	0.000322	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—SRC—sarcoma	5.55e-05	0.000322	CbGpPWpGaD
Thalidomide—Hypersensitivity—Epirubicin—sarcoma	5.54e-05	0.000208	CcSEcCtD
Thalidomide—Urticaria—Doxorubicin—sarcoma	5.53e-05	0.000208	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	5.52e-05	0.00032	CbGpPWpGaD
Thalidomide—Abdominal pain—Doxorubicin—sarcoma	5.5e-05	0.000207	CcSEcCtD
Thalidomide—Body temperature increased—Doxorubicin—sarcoma	5.5e-05	0.000207	CcSEcCtD
Thalidomide—NFKB1—Developmental Biology—MMP2—sarcoma	5.45e-05	0.000317	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—KIT—sarcoma	5.43e-05	0.000315	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TLE1—sarcoma	5.42e-05	0.000314	CbGpPWpGaD
Thalidomide—Asthenia—Epirubicin—sarcoma	5.4e-05	0.000203	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	5.39e-05	0.000313	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—TP53—sarcoma	5.35e-05	0.000311	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—NRAS—sarcoma	5.34e-05	0.00031	CbGpPWpGaD
Thalidomide—Pruritus—Epirubicin—sarcoma	5.32e-05	0.0002	CcSEcCtD
Thalidomide—FGFR2—B Cell Activation—HRAS—sarcoma	5.31e-05	0.000308	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ATF1—sarcoma	5.28e-05	0.000306	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—KIT—sarcoma	5.22e-05	0.000303	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CREB1—sarcoma	5.17e-05	0.0003	CbGpPWpGaD
Thalidomide—PTGS2—C-MYB transcription factor network—HRAS—sarcoma	5.17e-05	0.0003	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—KIT—sarcoma	5.15e-05	0.000299	CbGpPWpGaD
Thalidomide—Diarrhoea—Epirubicin—sarcoma	5.15e-05	0.000193	CcSEcCtD
Thalidomide—FGFR2—Disease—PLCG1—sarcoma	5.13e-05	0.000298	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—EGFR—sarcoma	5.13e-05	0.000298	CbGpPWpGaD
Thalidomide—Hypersensitivity—Doxorubicin—sarcoma	5.13e-05	0.000193	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	5.1e-05	0.000296	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—KDR—sarcoma	5.09e-05	0.000295	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—HRAS—sarcoma	5.08e-05	0.000295	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—sarcoma	5.02e-05	0.000291	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—MYC—sarcoma	5.01e-05	0.000291	CbGpPWpGaD
Thalidomide—Asthenia—Doxorubicin—sarcoma	4.99e-05	0.000188	CcSEcCtD
Thalidomide—Dizziness—Epirubicin—sarcoma	4.97e-05	0.000187	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—CREB1—sarcoma	4.97e-05	0.000288	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—KIT—sarcoma	4.95e-05	0.000287	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CXCR4—sarcoma	4.93e-05	0.000286	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—KRAS—sarcoma	4.93e-05	0.000286	CbGpPWpGaD
Thalidomide—Pruritus—Doxorubicin—sarcoma	4.92e-05	0.000185	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—CREB1—sarcoma	4.91e-05	0.000285	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—EGFR—sarcoma	4.9e-05	0.000285	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	4.88e-05	0.000284	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—EGFR—sarcoma	4.86e-05	0.000282	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—KRAS—sarcoma	4.84e-05	0.000281	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFC—sarcoma	4.82e-05	0.00028	CbGpPWpGaD
Thalidomide—Vomiting—Epirubicin—sarcoma	4.78e-05	0.00018	CcSEcCtD
Thalidomide—Diarrhoea—Doxorubicin—sarcoma	4.76e-05	0.000179	CcSEcCtD
Thalidomide—Rash—Epirubicin—sarcoma	4.74e-05	0.000178	CcSEcCtD
Thalidomide—Dermatitis—Epirubicin—sarcoma	4.74e-05	0.000178	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	4.74e-05	0.000275	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CREB1—sarcoma	4.71e-05	0.000274	CbGpPWpGaD
Thalidomide—Headache—Epirubicin—sarcoma	4.71e-05	0.000177	CcSEcCtD
Thalidomide—Dizziness—Doxorubicin—sarcoma	4.6e-05	0.000173	CcSEcCtD
Thalidomide—FGFR2—Signaling by NGF—KRAS—sarcoma	4.6e-05	0.000267	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—sarcoma	4.59e-05	0.000266	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFC—sarcoma	4.57e-05	0.000265	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	4.53e-05	0.000263	CbGpPWpGaD
Thalidomide—Nausea—Epirubicin—sarcoma	4.47e-05	0.000168	CcSEcCtD
Thalidomide—TNF—Developmental Biology—CREB1—sarcoma	4.46e-05	0.000259	CbGpPWpGaD
Thalidomide—Vomiting—Doxorubicin—sarcoma	4.42e-05	0.000166	CcSEcCtD
Thalidomide—Rash—Doxorubicin—sarcoma	4.39e-05	0.000165	CcSEcCtD
Thalidomide—Dermatitis—Doxorubicin—sarcoma	4.38e-05	0.000165	CcSEcCtD
Thalidomide—Headache—Doxorubicin—sarcoma	4.36e-05	0.000164	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—MDM2—sarcoma	4.28e-05	0.000248	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	4.25e-05	0.000247	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	4.24e-05	0.000246	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	4.21e-05	0.000245	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HRAS—sarcoma	4.19e-05	0.000243	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—CTNNB1—sarcoma	4.18e-05	0.000243	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—MMP2—sarcoma	4.15e-05	0.000241	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—FOXO1—sarcoma	4.15e-05	0.000241	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PDGFRB—sarcoma	4.15e-05	0.000241	CbGpPWpGaD
Thalidomide—Nausea—Doxorubicin—sarcoma	4.13e-05	0.000155	CcSEcCtD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—sarcoma	4.12e-05	0.000239	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—HRAS—sarcoma	4.12e-05	0.000239	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—MDM2—sarcoma	4.11e-05	0.000239	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PDGFRA—sarcoma	4.08e-05	0.000237	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—MDM2—sarcoma	4.06e-05	0.000236	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—FOXO1—sarcoma	3.94e-05	0.000229	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PDGFRB—sarcoma	3.93e-05	0.000228	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—HRAS—sarcoma	3.91e-05	0.000227	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—MDM2—sarcoma	3.9e-05	0.000226	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PDGFRA—sarcoma	3.87e-05	0.000225	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FLT1—sarcoma	3.85e-05	0.000224	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TLE1—sarcoma	3.84e-05	0.000223	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	3.81e-05	0.000221	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PLCG1—sarcoma	3.78e-05	0.00022	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—SRC—sarcoma	3.78e-05	0.000219	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—JUN—sarcoma	3.72e-05	0.000216	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	3.71e-05	0.000215	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CTNNB1—sarcoma	3.69e-05	0.000214	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—VEGFA—sarcoma	3.68e-05	0.000214	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FLT1—sarcoma	3.65e-05	0.000212	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FOXO1—sarcoma	3.64e-05	0.000211	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCR4—sarcoma	3.64e-05	0.000211	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—NRAS—sarcoma	3.63e-05	0.000211	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PDGFRB—sarcoma	3.63e-05	0.000211	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ATF1—sarcoma	3.59e-05	0.000209	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PLCG1—sarcoma	3.59e-05	0.000208	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PDGFRA—sarcoma	3.58e-05	0.000208	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—JUN—sarcoma	3.53e-05	0.000205	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CTNNB1—sarcoma	3.5e-05	0.000203	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NPM1—sarcoma	3.46e-05	0.000201	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCR4—sarcoma	3.45e-05	0.0002	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	3.41e-05	0.000198	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ATF1—sarcoma	3.41e-05	0.000198	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	3.34e-05	0.000194	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—SRC—sarcoma	3.34e-05	0.000194	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—EGFR—sarcoma	3.31e-05	0.000192	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—NRAS—sarcoma	3.21e-05	0.000186	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—SRC—sarcoma	3.2e-05	0.000186	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—CTNNB1—sarcoma	3.18e-05	0.000185	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ENO2—sarcoma	3.17e-05	0.000184	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—SRC—sarcoma	3.17e-05	0.000184	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KIT—sarcoma	3.16e-05	0.000184	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	3.15e-05	0.000183	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—HBA1—sarcoma	3.15e-05	0.000183	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—KRAS—sarcoma	3.13e-05	0.000182	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—NRAS—sarcoma	3.08e-05	0.000179	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—NRAS—sarcoma	3.05e-05	0.000177	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—SRC—sarcoma	3.04e-05	0.000177	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CREB1—sarcoma	3.01e-05	0.000175	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KIT—sarcoma	3e-05	0.000174	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ENO2—sarcoma	3e-05	0.000174	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—NRAS—sarcoma	2.92e-05	0.00017	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—EGFR—sarcoma	2.92e-05	0.00017	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—SRC—sarcoma	2.88e-05	0.000167	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CREB1—sarcoma	2.86e-05	0.000166	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IGF1R—sarcoma	2.82e-05	0.000164	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—EGFR—sarcoma	2.81e-05	0.000163	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—VEGFA—sarcoma	2.8e-05	0.000163	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	2.8e-05	0.000163	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—EGFR—sarcoma	2.77e-05	0.000161	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KIT—sarcoma	2.77e-05	0.000161	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—NRAS—sarcoma	2.77e-05	0.000161	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—KRAS—sarcoma	2.76e-05	0.00016	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PLCG1—sarcoma	2.69e-05	0.000156	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FOXO1—sarcoma	2.69e-05	0.000156	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PDGFRB—sarcoma	2.68e-05	0.000156	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IGF1R—sarcoma	2.68e-05	0.000155	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—EGFR—sarcoma	2.66e-05	0.000155	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—HRAS—sarcoma	2.66e-05	0.000154	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—KRAS—sarcoma	2.65e-05	0.000154	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CREB1—sarcoma	2.64e-05	0.000153	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PDGFRA—sarcoma	2.64e-05	0.000153	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—KRAS—sarcoma	2.62e-05	0.000152	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FOXO1—sarcoma	2.55e-05	0.000148	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PLCG1—sarcoma	2.55e-05	0.000148	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PDGFRB—sarcoma	2.54e-05	0.000148	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EGFR—sarcoma	2.52e-05	0.000146	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—KRAS—sarcoma	2.52e-05	0.000146	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ENO2—sarcoma	2.51e-05	0.000146	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PDGFRA—sarcoma	2.5e-05	0.000145	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—HBA1—sarcoma	2.5e-05	0.000145	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MDM2—sarcoma	2.49e-05	0.000145	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CXCR4—sarcoma	2.45e-05	0.000142	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—KRAS—sarcoma	2.38e-05	0.000138	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ENO2—sarcoma	2.37e-05	0.000137	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MDM2—sarcoma	2.36e-05	0.000137	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ENO2—sarcoma	2.36e-05	0.000137	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—HBA1—sarcoma	2.35e-05	0.000137	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—HRAS—sarcoma	2.35e-05	0.000136	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—HBA1—sarcoma	2.35e-05	0.000136	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HRAS—sarcoma	2.25e-05	0.000131	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ENO2—sarcoma	2.23e-05	0.00013	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HRAS—sarcoma	2.23e-05	0.000129	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL2—sarcoma	2.23e-05	0.000129	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KDR—sarcoma	2.22e-05	0.000129	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—HBA1—sarcoma	2.22e-05	0.000129	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MDM2—sarcoma	2.18e-05	0.000127	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—JUN—sarcoma	2.17e-05	0.000126	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CTNNB1—sarcoma	2.15e-05	0.000125	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HRAS—sarcoma	2.14e-05	0.000124	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PLCG1—sarcoma	2.13e-05	0.000124	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL2—sarcoma	2.11e-05	0.000123	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KDR—sarcoma	2.11e-05	0.000122	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—JUN—sarcoma	2.06e-05	0.000119	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KIT—sarcoma	2.05e-05	0.000119	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CTNNB1—sarcoma	2.04e-05	0.000118	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—HRAS—sarcoma	2.03e-05	0.000118	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PLCG1—sarcoma	2.01e-05	0.000117	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PLCG1—sarcoma	2e-05	0.000116	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CREB1—sarcoma	1.95e-05	0.000113	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—SRC—sarcoma	1.94e-05	0.000113	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KIT—sarcoma	1.94e-05	0.000113	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PLCG1—sarcoma	1.89e-05	0.00011	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CTNNB1—sarcoma	1.88e-05	0.000109	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—NRAS—sarcoma	1.87e-05	0.000109	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CREB1—sarcoma	1.85e-05	0.000107	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—SRC—sarcoma	1.84e-05	0.000107	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ENO2—sarcoma	1.83e-05	0.000106	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HBA1—sarcoma	1.81e-05	0.000105	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FOXO1—sarcoma	1.81e-05	0.000105	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PDGFRB—sarcoma	1.8e-05	0.000105	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PDGFRA—sarcoma	1.78e-05	0.000103	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NRAS—sarcoma	1.77e-05	0.000103	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EGFR—sarcoma	1.7e-05	9.89e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SRC—sarcoma	1.7e-05	9.88e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ENO2—sarcoma	1.66e-05	9.66e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HBA1—sarcoma	1.65e-05	9.6e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NRAS—sarcoma	1.64e-05	9.51e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EGFR—sarcoma	1.62e-05	9.38e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MDM2—sarcoma	1.61e-05	9.36e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KRAS—sarcoma	1.61e-05	9.34e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PLCG1—sarcoma	1.55e-05	8.99e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MDM2—sarcoma	1.53e-05	8.88e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KRAS—sarcoma	1.53e-05	8.86e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MYC—sarcoma	1.53e-05	8.86e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EGFR—sarcoma	1.49e-05	8.66e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2—sarcoma	1.44e-05	8.36e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ENO2—sarcoma	1.42e-05	8.26e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HBA1—sarcoma	1.41e-05	8.21e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PLCG1—sarcoma	1.41e-05	8.2e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KRAS—sarcoma	1.41e-05	8.18e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCND1—sarcoma	1.4e-05	8.15e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—JUN—sarcoma	1.4e-05	8.13e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CTNNB1—sarcoma	1.39e-05	8.07e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KIT—sarcoma	1.38e-05	7.99e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—sarcoma	1.37e-05	7.94e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2—sarcoma	1.37e-05	7.93e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCND1—sarcoma	1.33e-05	7.73e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—JUN—sarcoma	1.33e-05	7.72e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CTNNB1—sarcoma	1.32e-05	7.66e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CREB1—sarcoma	1.31e-05	7.61e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—sarcoma	1.3e-05	7.53e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SRC—sarcoma	1.26e-05	7.29e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—sarcoma	1.22e-05	7.1e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NRAS—sarcoma	1.21e-05	7.02e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PLCG1—sarcoma	1.21e-05	7.01e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—sarcoma	1.2e-05	6.96e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SRC—sarcoma	1.19e-05	6.92e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—sarcoma	1.16e-05	6.74e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NRAS—sarcoma	1.15e-05	6.66e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MYC—sarcoma	1.13e-05	6.54e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGFR—sarcoma	1.1e-05	6.39e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MDM2—sarcoma	1.08e-05	6.3e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MYC—sarcoma	1.07e-05	6.2e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGFR—sarcoma	1.04e-05	6.07e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KRAS—sarcoma	1.04e-05	6.04e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KRAS—sarcoma	9.87e-06	5.73e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CTNNB1—sarcoma	9.35e-06	5.43e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—sarcoma	9.25e-06	5.37e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—sarcoma	8.84e-06	5.13e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—sarcoma	8.77e-06	5.09e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SRC—sarcoma	8.45e-06	4.91e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—sarcoma	8.39e-06	4.87e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NRAS—sarcoma	8.13e-06	4.72e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MYC—sarcoma	7.57e-06	4.4e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGFR—sarcoma	7.41e-06	4.3e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KRAS—sarcoma	7e-06	4.06e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—sarcoma	5.95e-06	3.45e-05	CbGpPWpGaD
